Structure Therapeutics — Third Quarter 2026 Earnings Summary

Structure Therapeutics reported a net loss of $144.8 million for the third quarter of 2026, driven by increased research and development expenses to $134.6 million as it advances its aleniglipron and ACCG-2671 clinical programs. The company's Phase 3 ACCOMPLISH-1 and ACCOMPLISH-2 trials for aleniglipron are currently enrolling, with topline data expected in the second half of 2028. Additionally, multiple ascending dose trials for the oral amylin receptor agonist ACCG-2671 are underway, with results anticipated in the first half of 2027. As of September 30, 2026, the company held $1.2 billion in cash and short-term investments, which is projected to fund operations and key clinical milestones through 2028.